139 related articles for article (PubMed ID: 37740611)
1. Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition.
Gómez C; Alimajstorovic Z; Othonos N; Winter DV; White S; Lavery GG; Tomlinson JW; Sinclair AJ; Odermatt A
Br J Pharmacol; 2024 Mar; 181(5):698-711. PubMed ID: 37740611
[TBL] [Abstract][Full Text] [Related]
2. The ratio of ursodeoxycholyltaurine to 7-oxolithocholyltaurine serves as a biomarker of decreased 11β-hydroxysteroid dehydrogenase 1 activity in mouse.
Weingartner M; Stücheli S; Kratschmar DV; Birk J; Klusonova P; Chapman KE; Lavery GG; Odermatt A
Br J Pharmacol; 2021 Aug; 178(16):3309-3326. PubMed ID: 33450045
[TBL] [Abstract][Full Text] [Related]
3. A simple LC-MS/MS method for the determination of cortisol, cortisone and tetrahydro-metabolites in human urine: assay development, validation and application in depression patients.
Zhai X; Chen F; Zhu C; Lu Y
J Pharm Biomed Anal; 2015 Mar; 107():450-5. PubMed ID: 25668797
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.
Tomlinson JW; Sherlock M; Hughes B; Hughes SV; Kilvington F; Bartlett W; Courtney R; Rejto P; Carley W; Stewart PM
J Clin Endocrinol Metab; 2007 Mar; 92(3):857-64. PubMed ID: 17200165
[TBL] [Abstract][Full Text] [Related]
5. 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.
Campino C; Carvajal CA; Cornejo J; San Martín B; Olivieri O; Guidi G; Faccini G; Pasini F; Sateler J; Baudrand R; Mosso L; Owen GI; Kalergis AM; Padilla O; Fardella CE
Endocrine; 2010 Feb; 37(1):106-14. PubMed ID: 19882252
[TBL] [Abstract][Full Text] [Related]
6. Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia.
Abbas A; Schini M; Ainsworth G; Brown SR; Oughton J; Crowley RK; Cooper MS; Fairclough RJ; Eastell R; Stewart PM
J Clin Endocrinol Metab; 2022 Jun; 107(7):2026-2035. PubMed ID: 35275196
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
8. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
Webster SP; McBride A; Binnie M; Sooy K; Seckl JR; Andrew R; Pallin TD; Hunt HJ; Perrior TR; Ruffles VS; Ketelbey JW; Boyd A; Walker BR
Br J Pharmacol; 2017 Mar; 174(5):396-408. PubMed ID: 28012176
[TBL] [Abstract][Full Text] [Related]
9. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
Tsilchorozidou T; Honour JW; Conway GS
J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye.
Anderson S; Carreiro S; Quenzer T; Gale D; Xiang C; Gukasyan H; Lafontaine J; Cheng H; Krauss A; Prasanna G
J Ocul Pharmacol Ther; 2009 Jun; 25(3):215-22. PubMed ID: 19456256
[TBL] [Abstract][Full Text] [Related]
11. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
12. Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Wiegand S; Richardt A; Remer T; Wudy SA; Tomlinson JW; Hughes B; Grüters A; Stewart PM; Strasburger CJ; Quinkler M
Eur J Endocrinol; 2007 Sep; 157(3):319-24. PubMed ID: 17766714
[TBL] [Abstract][Full Text] [Related]
13. Expression of 11β-hydroxysteroid dehydrogenase 1 and 2 in patients with chronic rhinosinusitis and their possible contribution to local glucocorticoid activation in sinus mucosa.
Jun YJ; Park SJ; Kim TH; Lee SH; Lee KJ; Hwang SM; Lee SH
J Allergy Clin Immunol; 2014 Oct; 134(4):926-934.e6. PubMed ID: 24810847
[TBL] [Abstract][Full Text] [Related]
14. In vivo activity of 11beta-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance.
Mai K; Kullmann V; Bobbert T; Maser-Gluth C; Möhlig M; Bähr V; Pfeiffer AF; Spranger J; Diederich S
Clin Endocrinol (Oxf); 2005 Oct; 63(4):442-9. PubMed ID: 16181237
[TBL] [Abstract][Full Text] [Related]
15. LC-MS/MS Method for the Simultaneous Determination of Free Urinary Steroids.
Allende F; Solari S; Campino C; Carvajal CA; Lagos CF; Vecchiola A; Valdivia C; Baudrand R; Owen GI; Fardella CE
Chromatographia; 2014; 77(7-8):637-642. PubMed ID: 24683202
[TBL] [Abstract][Full Text] [Related]
16. 11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
Müssig K; Remer T; Haupt A; Gallwitz B; Fritsche A; Häring HU; Maser-Gluth C
Obesity (Silver Spring); 2008 Jun; 16(6):1256-60. PubMed ID: 18421276
[TBL] [Abstract][Full Text] [Related]
17. Hexose-6-phosphate dehydrogenase modulates 11beta-hydroxysteroid dehydrogenase type 1-dependent metabolism of 7-keto- and 7beta-hydroxy-neurosteroids.
Nashev LG; Chandsawangbhuwana C; Balazs Z; Atanasov AG; Dick B; Frey FJ; Baker ME; Odermatt A
PLoS One; 2007 Jun; 2(6):e561. PubMed ID: 17593962
[TBL] [Abstract][Full Text] [Related]
18. Association studies between microsatellite markers within the gene encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism.
Draper N; Echwald SM; Lavery GG; Walker EA; Fraser R; Davies E; Sørensen TI; Astrup A; Adamski J; Hewison M; Connell JM; Pedersen O; Stewart PM
J Clin Endocrinol Metab; 2002 Nov; 87(11):4984-90. PubMed ID: 12414862
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
20. 11β-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the story.
Odermatt A; Klusonova P
J Steroid Biochem Mol Biol; 2015 Jul; 151():85-92. PubMed ID: 25151952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
